Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director | August 27, 2026 | August 31, 2026 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | June 05, 2026 | June 17, 2026 |
| PALATIN TECHNOLOGIES INCPTN · Entity 7649 | Director | August 03, 2026 | August 05, 2026 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | January 03, 2023 | January 05, 2023 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-27 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-27 · Exercise / conversion · Acquired 41,927 · Balance 41,927 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. Row 2 · 2026-08-27 · Exercise / conversion · Acquired 3,583 · Balance 45,510 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. Row 3 · 2026-08-27 · Sale · Disposed 42,349 · Balance 3,161 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 4 · 2026-08-27 · Sale · Disposed 3,161 · Balance 0 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.64 · Expires 2035-06-04 | Direct | 2,773 |
Reported balance
After 2026-08-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-27 · Exercise / conversion · Disposed 41,927 · Balance 2,773 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F4: These options are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-27 · Exercise / conversion · Disposed 3,583 · Balance 0 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F4: These options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: These options are fully vested.
Edgewise Therapeutics, Inc.
Report date June 05, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05 | Direct | 16,377 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.
PALATIN TECHNOLOGIES INC
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.70 · Expires 2037-08-03 | Direct | 3,497 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Other · Acquired 2,400 · Balance 3,497 F1: Stock Option granted under the 2011 Stock Incentive Plan as amended. The option vests as to 50% on August 3, 2027 and as to the remaining 50% on August 3, 2028. The option was granted by the Compensation Committee on August 3, 2026, and there was no impediment to the grant of option. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Option granted under the 2011 Stock Incentive Plan as amended. The option vests as to 50% on August 3, 2027 and as to the remaining 50% on August 3, 2028. The option was granted by the Compensation Committee on August 3, 2026, and there was no impediment to the grant of option.
VIVEVE MEDICAL, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 36,000 · Balance 36,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2025-08-11 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Disposition to issuer · Disposed 44,474 · Balance 0 F1: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-07 · Disposition to issuer · Disposed 32,069 · Balance 0 F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-07 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2019 Filed May 31, 2019 16:31 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 35,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001437749-19-011165 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 35,000 non-qualified stock options on May 29, 2019 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 100 | $0.69 | $68.78 |
DisclosureSEC source: 0001654954-18-013089 · section16.xml · nonDerivative · entry 5 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,999 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 2,100 | $0.69 | $1,439.55 |
DisclosureSEC source: 0001654954-18-013089 · section16.xml · nonDerivative · entry 4 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,899 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 100 | $0.69 | $68.54 |
DisclosureSEC source: 0001654954-18-013089 · section16.xml · nonDerivative · entry 3 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,799 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 100 | $0.69 | $68.53 |
DisclosureSEC source: 0001654954-18-013089 · section16.xml · nonDerivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,699 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 9,600 | $0.69 | $6,577.92 |
DisclosureSEC source: 0001654954-18-013089 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,599 Read SEC document |
| October 23, 2018 Filed Oct 25, 2018 12:48 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 17,500 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001437749-18-018777 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-10-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 17,500 non-qualified stock options on October 23, 2018 (the "Grant Date"). The non-qualified stock options shall vest in full on May 22, 2019. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 20:46 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001209191-18-039891 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-06-26 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 20:45 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007111 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-06-26 F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2018. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 20:45 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007111 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,333 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 26, 2019. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 26, 2019. Read SEC document |
| May 22, 2018 Filed May 23, 2018 16:20 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 17,500 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-18-010594 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-05-21 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 17,500 non-qualified stock options on May 22, 2018 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:27 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001654954-17-011597 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-12-12 F2 · derivative.exercise_date: Options vest at the rate of one-third per year, starting on December 12, 2018. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:27 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-011597 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,500 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of one-third per year starting on December 12, 2018. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of one-third per year starting on December 12, 2018. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:10 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001209191-17-059631 · doc4.xml · derivative · entry 3 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F3 · price: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F3 · derivative.exercise_date: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:10 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,069 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0001209191-17-059631 · doc4.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,069 shares Expires 2026-05-18 F2 · price: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F2 · derivative.exercise_date: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:10 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,474 | Not disclosed Strike: $4.85 | Not disclosed |
DisclosureSEC source: 0001209191-17-059631 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,474 shares Expires 2025-08-11 F1 · price: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. F1 · derivative.exercise_date: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:36 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 17,500 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001437749-17-015822 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-09-05 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 17,500 non-qualified stock options on September 6, 2017 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:20 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001654954-17-005815 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2027-06-20 F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2017. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:20 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005815 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,500 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 20, 2018. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 20, 2018. Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:28 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001209191-17-035828 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board. Read SEC document |
| December 23, 2016 Filed Dec 28, 2016 21:00 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 25,160 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001437749-16-043881 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,160 Underlying: Common Stock · 25,160 shares Expires 2026-12-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 25,160 non-qualified stock options on December 23, 2016 (the "Grant Date"). The non-qualified stock options will vest in equal monthly increments over 48 months following the Grant Date. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 16:03 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 1,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-16-042056 · rdgdoc.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,482 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 1,442 shares of common stock on November 9, 2016 (the "Grant Date"). The restricted stock award vested in the full on the Grant Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.